Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes
Overview
Affiliations
Intratumoral hypoxia has been associated with invasion, metastasis, and treatment failure, prompting the need for a global characterization of the response to hypoxic conditions. The current study presents the results of a large-scale RNA sequencing (RNA-seq) effort, analyzing 31 breast cancer cell lines representative of breast cancer subtypes or normal mammary epithelial (NME) cells exposed to control tissue culture conditions (20% O) or hypoxic conditions (1% O). The results demonstrate that NME have a stronger response to hypoxia both in terms of number of genes induced by hypoxia as well as level of expression. A conserved 42-gene hypoxia signature shared across PAM50 subtypes and genes that are exclusively upregulated in Luminal A, Luminal B, and normal-like mammary epithelial cells is identified. The 42-gene expression signature is enriched in a subset of basal-like cell lines and tumors and differentiates survival among patients with basal-like tumors. Mechanistically, the hypoxia-inducible factors (HIF-1 and/or HIF-2) mediate the conserved hypoxic response. Also, four novel hypoxia-regulated and HIF-1-responsive genes were identified as part of the conserved signature. This dataset provides a novel resource to query transcriptional changes that occur in response to hypoxia and serves as a starting point for a clinical assay to aid in stratifying patients that would benefit from hypoxia-targeted therapies, some of which are currently in clinical trials. IMPLICATIONS: RNA-seq of 31 breast cancer cells exposed to control or hypoxic conditions reveals a conserved genomic signature that contains novel HIF-regulated genes and is prognostic for the survival of patients with triple-negative breast cancer.
CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer.
He K, Zheng J, Zhang T, Lv H, Wang K, Wang Z Eur J Med Res. 2025; 30(1):174.
PMID: 40089797 DOI: 10.1186/s40001-025-02293-0.
Seymour L, Nuru N, Johnson K, Gutierrez J, Njoku V, Darie C Molecules. 2025; 30(3).
PMID: 39942749 PMC: 11820228. DOI: 10.3390/molecules30030645.
Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.
Di Giovannantonio M, Hartley F, Elshenawy B, Barberis A, Hudson D, Shafique H Cell Genom. 2025; 5(2):100764.
PMID: 39892389 PMC: 11872601. DOI: 10.1016/j.xgen.2025.100764.
Malcolm J, Bridge K, Holding A, Brackenbury W BMC Genomics. 2025; 26(1):59.
PMID: 39838295 PMC: 11748566. DOI: 10.1186/s12864-025-11216-6.
Shamis S, Quinn J, Al-Badran S, McKenzie M, Hatthakarnkul P, Lynch G Cancer Med. 2024; 13(23):e70274.
PMID: 39660488 PMC: 11632397. DOI: 10.1002/cam4.70274.